Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) is a biopharmaceutical company that develops and commercializes medicines across specialty therapeutic areas. Revenue comes from selling prescription pharmaceutical products, with key named instruments including exchangeable senior notes (1.50% due 2024, 2.00% due 2026, 3.125% due 2030) indicating a debt-carrying capital structure. The company is incorporated in Ireland and lists on the Nasdaq Global Select Market. Based on the FY2025 10-K filed February 24, 2026, the filing references defined product terms and equity programs including a 2011 Equity Incentive Plan and a 2007 Non-Employee Directors Stock Award Plan. The filing also references the U.S. Public Health Service's 340B program and the Affordable Care Act as relevant regulatory frameworks, and names counterparties including Aetna, Alkermes, and Adare Pharma Solutions. The revolving credit facility carries a maturity date of November 26, 2029, with a facility size of $885.0 million as amended.

Revenue model

Prescription pharmaceutical product sales, transactional revenue from commercialized medicines sold into specialty therapeutic markets.

Products and services

The filing references named exchangeable senior notes (2024 Notes at 1.50%, 2026 Notes at 2.00%, 2030 Notes at 3.125%) and equity incentive plans. Specific commercial drug products and brand names are listed in a defined terms section referencing acute lymphoblastic leukemia (ALL) as an end-market indication, per the FY2025 10-K filed February 24, 2026.

Customers and end markets

End markets include conditions such as acute lymphoblastic leukemia (ALL), per defined terms in the FY2025 10-K. The 340B program is referenced, indicating sales into U.S. covered entity channels such as qualifying hospitals and clinics. Aetna is named as a defined counterparty, suggesting payer relationships.

Value-chain role

Specialty pharmaceutical manufacturer and commercial-stage drug marketer selling branded prescription products through payer and specialty pharmacy channels.

Geographic exposure

Incorporated in Ireland; listed on the Nasdaq Global Select Market in the United States. U.S. regulatory frameworks (340B, ACA) are cited, indicating material U.S. commercial operations, per the FY2025 10-K filed February 24, 2026.

Source: SEC 10-K, filed 2026-02-24

Industry: Pharmaceutical Preparations Peers: AVADEL PHARMACEUTICALS PLC Endo International plc GH Research PLC ITERUM THERAPEUTICS PLC Keenova Therapeutics plc Nabriva Therapeutics plc Perrigo Company PLC